Statements (65)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquisition |
Iveric Bio (2022)
OSI Pharmaceuticals (2010) |
| gptkbp:awards |
recognized for innovation in healthcare
|
| gptkbp:ceo |
gptkb:Kenji_Yasukawa
|
| gptkbp:clinical_trial |
conducts Phase I to Phase III clinical trials
conducts clinical trials globally conducts clinical research for new therapies |
| gptkbp:collaborations |
collaborates with academic institutions
|
| gptkbp:community_engagement |
engages in community health programs
|
| gptkbp:cultural_diversity |
promotes diversity and inclusion in the workplace
|
| gptkbp:employees |
around 17,000
|
| gptkbp:financial_support |
provides patient support programs
|
| gptkbp:focus |
research and development
oncology infectious diseases transplantation urology |
| gptkbp:focuses_on |
gptkb:Research_and_Development
|
| gptkbp:founded |
gptkb:2005
|
| gptkbp:founded_in |
gptkb:2005
|
| gptkbp:founder |
gptkb:Yoshihiko_Hatanaka
|
| gptkbp:global_presence |
has a significant global presence
|
| gptkbp:has_partnerships_with |
Various healthcare organizations
|
| gptkbp:has_research_center |
has research centers in Japan and the US
|
| gptkbp:headquartered_in |
gptkb:Tokyo,_Japan
|
| gptkbp:headquarters |
gptkb:Tokyo,_Japan
|
| gptkbp:healthcare |
works with healthcare professionals globally
|
| https://www.w3.org/2000/01/rdf-schema#label |
Astellas Pharma
|
| gptkbp:innovation |
drives innovation in drug development
|
| gptkbp:instruction_set |
has a robust drug pipeline
|
| gptkbp:invention |
holds numerous patents in pharmaceuticals
|
| gptkbp:investment |
invests heavily in R& D
|
| gptkbp:is_a |
gptkb:pharmaceuticals
|
| gptkbp:is_known_for |
Innovative therapies
|
| gptkbp:leadership |
led by a diverse leadership team
|
| gptkbp:market |
operates in over 70 countries
|
| gptkbp:marketing_strategy |
develops market strategies for product launches
|
| gptkbp:mission |
dedicated to improving the health of people worldwide
|
| gptkbp:offers |
Prescription medications
|
| gptkbp:operates_in |
Global markets
|
| gptkbp:partnership |
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer |
| gptkbp:partnerships |
forms strategic partnerships with other companies
|
| gptkbp:philanthropy |
engages in philanthropic activities
|
| gptkbp:products |
antibiotics
oncology drugs immunosuppressants |
| gptkbp:provides_guidance_on |
contributes to clinical guidelines in healthcare.
|
| gptkbp:regulatory_compliance |
seeks regulatory approvals for new drugs
|
| gptkbp:research |
invests in scientific research initiatives
|
| gptkbp:research_areas |
focuses on multiple therapeutic areas
|
| gptkbp:revenue |
$12.5 billion (2020)
|
| gptkbp:social_responsibility |
supports various health initiatives
|
| gptkbp:stock_exchange |
gptkb:Tokyo_Stock_Exchange
|
| gptkbp:stock_symbol |
4503
|
| gptkbp:subsidiaries |
gptkb:Astellas_US_LLC
gptkb:Astellas_Pharma_Europe_Ltd. |
| gptkbp:supply_chain |
manages a global supply chain for pharmaceuticals
|
| gptkbp:sustainability |
committed to sustainable practices
|
| gptkbp:values |
committed to integrity and transparency
|
| gptkbp:vision |
aims to be a trusted partner in healthcare
|
| gptkbp:website |
www.astellas.com
|
| gptkbp:bfsParent |
gptkb:biotechnology
|
| gptkbp:bfsLayer |
3
|